Elevai Labs INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

30 Mar 2026

ELAB

10-K: PMGC posts small revenue, big loss, eyes IND in 2026

PMGC Holdings reported $0.59M in first-year operating revenue and a $7.75M net loss, executed dilutive financings backed by pledged subsidiaries, and plans to advance lead biotech asset EL-22 toward a U.S. IND in 2026.

NASDAQ

28 Mar 2025

ELAB

Elevai Labs INC

10-K: PMGC Holdings Shifts Focus to Biotech, Reports Full Year 2024 Results

PMGC Holdings Inc. divests its skincare business to concentrate on biotechnology assets, reporting a net loss of $6.25 million for fiscal year 2024.

NASDAQ

29 Mar 2024

ELAB

Elevai Labs INC

10-K: Elevai Labs Inc. Files 10-K Report for Fiscal Year 2023, Citing Growth and Future Expansion Plans

Elevai Labs Inc. reports increased revenue and outlines strategic growth plans in its annual 10-K filing, while also acknowledging ongoing financial challenges.